Repository logo
 

Modeling HNF1B-associated monogenic diabetes using human iPSCs reveals an early stage impairment of the pancreatic developmental program.

Accepted version
Peer-reviewed

Change log

Authors

El-Khairi, Ranna 
Olszanowski, Evelyn 
Muraro, Daniele 
Tilgner, Katarzyna 

Abstract

Heterozygous mutations in HNF1B in humans result in a multisystem disorder, including pancreatic hypoplasia and diabetes mellitus. Here we used a well-controlled human induced pluripotent stem cell pancreatic differentiation model to elucidate the molecular mechanisms underlying HNF1B-associated diabetes. Our results show that lack of HNF1B blocks specification of pancreatic fate from the foregut progenitor (FP) stage, but HNF1B haploinsufficiency allows differentiation of multipotent pancreatic progenitor cells (MPCs) and insulin-secreting β-like cells. We show that HNF1B haploinsufficiency impairs cell proliferation in FPs and MPCs. This could be attributed to impaired induction of key pancreatic developmental genes, including SOX11, ROBO2, and additional TEAD1 target genes whose function is associated with MPC self-renewal. In this work we uncover an exhaustive list of potential HNF1B gene targets during human pancreas organogenesis whose downregulation might underlie HNF1B-associated diabetes onset in humans, thus providing an important resource to understand the pathogenesis of this disease.

Description

Keywords

HNF1B, MODY5, diabetes, differentiation, human induced pluripotent stem cells, iPSC, in vitro, monogenic, pancreas, β cell, Biomarkers, CRISPR-Cas Systems, Cell Differentiation, Cell Lineage, Diabetes Mellitus, Disease Susceptibility, Fluorescent Antibody Technique, Gene Editing, Gene Expression Profiling, Gene Expression Regulation, Developmental, Haploinsufficiency, Hepatocyte Nuclear Factor 1-beta, Humans, Immunophenotyping, Induced Pluripotent Stem Cells, Insulin-Secreting Cells, Models, Biological, Organogenesis, Pancreas, Signal Transduction

Journal Title

Stem Cell Reports

Conference Name

Journal ISSN

2213-6711
2213-6711

Volume Title

16

Publisher

Elsevier BV

Rights

All rights reserved
Sponsorship
Wellcome Trust (203151/Z/16/Z)
National Institute for Health and Care Research (IS-BRC-1215-20014)
Medical Research Council (MC_PC_17230)
We thank Prof. Andrew T. Hattersley (Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK) for important discussions orienting the study. S.A.R.-S. is a career investigator from the Consejo Nacional de Investigaciones Científicas y Técnicas of Argentina (CONICET). This work was supported by the CONICET/Royal Society International Exchanges Cost Share 2018 (IEC\R2\181023) to L.V. and S.A.R.-S. The S.A.R.-S. laboratory is funded by grants from Agencia Nacional de Promoción Científica y Tecnológica of Argentina (PICT-2015 3605, PICT-2017 2071) and the Universidad de Buenos Aires (UBACYT20020170200156BA). The L.V. laboratory is funded by the ERC advanced grant New-Chol, the core support grant from the Wellcome Trust and Medical Research Council of the Wellcome–MRC Cambridge Stem Cell Institute, and the Cambridge University Hospitals NIHR Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. RHK was funded by the Cambridge Wellcome Trust PhD clinical program, CS by ASTAR studentship, PM, DM, SV, KT, MC by the Sanger Wellcome Institute. E.O. is supported by a PhD fellowship from the CONICET.